Cogent Biosciences (COGT) Accumulated Depreciation (2017 - 2025)

Cogent Biosciences (COGT) has 9 years of Accumulated Depreciation data on file, last reported at $8.7 million in Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 41.93% year-over-year to $8.7 million in Q4 2025; TTM through Dec 2025 was $8.7 million, a 41.93% increase from a year earlier, with the FY2025 full-year figure at $8.7 million, up 41.93% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $8.7 million, up from $6.1 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for COGT reached as high as $8.7 million in Q4 2025 and fell as low as $559000.0 in Q4 2021.
• Historically, Accumulated Depreciation has averaged $4.1 million across 5 years, with a median of $3.7 million in 2023.
• Across the five-year window, Accumulated Depreciation soared 35.68% in 2021 and jumped 161.6% in 2023, its largest moves.
• Year by year, Accumulated Depreciation stood at $559000.0 in 2021, then surged by 150.63% to $1.4 million in 2022, then soared by 161.6% to $3.7 million in 2023, then surged by 66.85% to $6.1 million in 2024, then surged by 41.93% to $8.7 million in 2025.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $8.7 million in Q4 2025, $6.1 million in Q4 2024, and $3.7 million in Q4 2023.